Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Finalizes Premarket Cybersecurity Requirements

Executive Summary

The Canadian regulator says that medical device manufacturers must demonstrate in their premarket license or license amendment applications that adequate provisions are in place to monitor, prevent and respond to post‐market cybersecurity events.

You may also be interested in...



US, Canada Setting Trend For Global Cybersecurity Guidance

A draft IMDRF guidance released this month aims to set the trend for how regulators around the world oversee cybersecurity of medical devices. According to experts, the document also foreshadows what sponsors can expect from the US FDA in areas such as developing a software bill of materials, as the agency updates its own cybersecurity guidances.

Global Medtech Guidance Tracker: June 2019

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four new guidance documents have been posted on the tracker since its last update.

Canadian Guidance On Pre-Market Cybersecurity Requirements Expected This Year

Canada's pre-market evaluation process for medical devices will soon include evaluating the adequacy of a manufacturer's risk control measures to address cybersecurity concerns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel